|
Malignant neoplasm of liver
|
0.560 |
Biomarker
|
disease |
BEFREE |
Based on the identification of GNMT as a 4 S polyaromatic hydrocarbon-binding protein, we used liver cancer cell lines that expressed GNMT either transiently or stably in cDNA transfections to analyze the role of GNMT in the benzo(a)pyrene (BaP) detoxification pathway.
|
15150120 |
2004 |
|
Malignant neoplasm of liver
|
0.560 |
Biomarker
|
disease |
BEFREE |
Using genotypic characterization of GNMT in hepatoma cell lines and in a Taiwanese population with a high incidence of liver cancer we have investigated the role of this gene in the progression of liver cancer.
|
12566309 |
2003 |
|
Malignant neoplasm of liver
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
Reduced GNMT expression was also found in human HCC tissue and liver cancer cell lines.
|
31086990 |
2019 |
|
Malignant neoplasm of liver
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of GNMT gene expression may be involved in the pathogenesis of liver cancer.
|
9495250 |
1998 |
|
Malignant neoplasm of liver
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
High rates of GNMT knockout mice developed HCC, while overexpression of GNMT prevented aflatoxin-induced carcinogenicity and inhibited liver cancer cell proliferation.
|
27153064 |
2016 |
|
Malignant neoplasm of liver
|
0.560 |
Biomarker
|
disease |
BEFREE |
Therefore, GNMT is a tumor suppressor gene for liver cancer, and it is associated with gender disparity in liver cancer susceptibility.
|
19035462 |
2009 |
|
Liver neoplasms
|
0.550 |
AlteredExpression
|
group |
BEFREE |
Injection of AAV serotype 8 (AAV8) vector carrying the GNMT gene (AAV8-GNMT) in Gnmt<sup>-/-</sup> mice increased GNMT expression and downregulated pro-inflammatory responses, resulting in reduced liver damage and incidence of liver tumors.
|
30217986 |
2018 |
|
Liver neoplasms
|
0.550 |
Biomarker
|
group |
BEFREE |
Glycine N-methyltransferase (GNMT) is a folate binding protein commonly diminished in human hepatoma yet its role in tumor development remains to be established.
|
23922098 |
2014 |
|
Liver neoplasms
|
0.550 |
Biomarker
|
group |
BEFREE |
The metabolic physiology that sustains liver tumor formation in GNMT-null mice is unknown.
|
30850319 |
2019 |
|
Liver neoplasms
|
0.550 |
Biomarker
|
group |
BEFREE |
GNMT serves multiple roles which include a methyl group transfer enzyme and a liver tumor suppressor.
|
30987732 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Overall, our findings suggest that reduced Gnmt expression caused by promoter hypermethylation is one of the key molecular events in the development of NAFLD-derived HCC and that assessing Gnmt methylation level may be useful for disease stratification.
|
31086990 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.350 |
Biomarker
|
disease |
BEFREE |
Different in vitro and in vivo NAFLD murine models were used to assess miR-873-5p/GNMT involvement in fatty liver progression through targeting of the miR-873-5p as NAFLD therapy.
|
31668391 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, GNMT was downregulated in the liver tissues from patients suffering with NAFLD as well as from mice fed a high-fat diet, high-cholesterol diet or methionine/choline-deficient diet.
|
22183894 |
2012 |
|
Non-alcoholic Fatty Liver Disease
|
0.350 |
Biomarker
|
disease |
BEFREE |
SHP was found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A) in cultured hepatic cells and the livers of different animal models of NAFLD: iatrogenic (tetracycline-treated rats), genetic (glycine N-methyltransferase-deficient mice), and nutritional (mice fed a methionine- and choline-deficient diet).
|
25576488 |
2015 |
|
Non-alcoholic Fatty Liver Disease
|
0.350 |
Biomarker
|
disease |
BEFREE |
A parallel animal model/human NAFLD exploratory metabolomics approach was employed, using ultra performance liquid chromatography-mass spectrometry (UPLC-MS) to analyze 42 serum samples collected from nondiabetic, morbidly obese, biopsy-proven NAFLD patients, and 17 animals belonging to the glycine N-methyltransferase knockout (GNMT-KO) NAFLD mouse model.
|
20684516 |
2010 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Here, we report on our efforts to characterize the haplotypes, loss of heterozygosity (LOH), and expression levels of the GNMT in prostate cancer.
|
17332283 |
2007 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
In addition, the expression of sarcosine biosynthetic enzyme, glycine N-methyltransferase (GNMT), was elevated in PCa tissues, while sarcosine dehydrogenase (SARDH) and pipecolic acid oxidase (PIPOX), which metabolize sarcosine, were reduced in prostate tumors.
|
23633921 |
2013 |
|
Malignant neoplasm of prostate
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
The GNMT short tandem repeat polymorphism 1 (STRP1), 4-bp insertion/deletion polymorphisms (INS/DEL) and the single nucleotide polymorphism rs10948059 were genotyped to test for their association with prostate cancer risk.
|
24800880 |
2014 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Total DNA methylation was decreased in PCa; control GNMT T carriers (T+) showed the highest level of DNA methylation.
|
22850906 |
2013 |
|
Nonalcoholic Steatohepatitis
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Total liver phosphatidylcholine content associates with non-alcoholic steatohepatitis and glycine N-methyltransferase expression.
|
31199045 |
2019 |
|
Nonalcoholic Steatohepatitis
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In NAFLD, GNMT expression is controlled by miR-873-5p in the hepatocytes, leading to disruptions in mitochondrial functionality in a preclinical murine non-alcoholic steatohepatitis (NASH) model.
|
31668391 |
2019 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
BEFREE |
In addition, the expression of sarcosine biosynthetic enzyme, glycine N-methyltransferase (GNMT), was elevated in PCa tissues, while sarcosine dehydrogenase (SARDH) and pipecolic acid oxidase (PIPOX), which metabolize sarcosine, were reduced in prostate tumors.
|
23633921 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In Taiwanese men, GNMT was found to be a tumor susceptibility gene for prostate cancer.
|
24800880 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Purified PL extract and PGG induced GNMT mRNA and protein expression in Huh7 human hepatoma cells and in xenograft tumors.
|
27153064 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the observed heterozygosity of GNMT decreases in tumor adjacent liver DNA from HCC patients compared with that observed in blood DNA from normal individuals and HCC patients.
|
12566309 |
2003 |